Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ancrod - Nordmark Arzneimittel

Drug Profile

Ancrod - Nordmark Arzneimittel

Alternative Names: NM-V; Viprinex

Latest Information Update: 03 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Neurobiological Technologies; Nordmark Arzneimittel
  • Class Antithrombotics; Serine endopeptidases; Venoms
  • Mechanism of Action Fibrinogen inhibitors; Plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Sensorineural hearing loss
  • Market Withdrawal Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral vascular disorders; Thromboembolism
  • Discontinued Stroke

Most Recent Events

  • 30 Oct 2018 Nordmark Arzneimittel completes a phase I/II trial in Sensorineural hearing loss in Czech Republic, Germany (SC) (IV) (NCT01621256)
  • 24 Jun 2018 Biomarkers information updated
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top